Lung cancer will soon join melanoma as a phase 3 indication for mRNA-4157, an asset Merck & Co last year endorsed to the tune of $250m.

A flurry of activity around USP1 inhibition suggests growing interest in this novel DNA damage response mechanism.

Adding a kinase inhibitor to PD-L1 plus chemo could make a real difference in first-line SCLC, a little-appreciated Chinese trial suggests.

Palazestrant joins vepdegestrant in pivotal development, as SERDs continue their rollercoaster ride.

Phase 1 data for divarasib in lung and colorectal cancers look good versus Lumakras and Krazati’s earlier showings.

A statistical analysis of Skyscraper-01’s second interim read is inadvertently posted on a Roche website.

However, the design of the Contact-02 study, and the relevance of the positive PFS endpoint, will be debated.